All In Biotech

Drug Trial Radar · NCT06928272

Long Covid (LC)-REVITALIZE - A Long Covid Repurposed Drug Study

LC-REVITALIZE - A Long Covid Repurposed Drug Study

Last checked: Nov 20, 2026Latest source record: Oct 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 348 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

348

Planned (sponsor's estimate)

Start

Sep 10, 2025

Primary completion

Dec 2026

Study completion Dec 2027

Sponsor

Lead sponsor
Douglas D. FraserAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Apr 15, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The Long-Covid (LC)-Revitalize clinical study is testing repurposed drug treatments for Long Covid, involving adult participants from Brazil, Canada, Italy, South Africa, Uganda, the United States, and Zambia. To qualify, participants must have had Covid-19 and experienced Long Covid symptoms for at least three months. The main goal of the study is to determine whether the drug treatments can improve symptoms in five key areas: 1) fatigue, 2) breathing, 3) memory, thinking, and communication, 4) muscle and joint pain, and 5) circulation. A secondary goal is to assess changes in the body, such as reducing inflammation, as well as to confirm the safety and tolerability of the treatments. In the first phase, 348 participants will take either one of two existing medications (upadacitinib or pirfenidone) or a placebo (a pill with no active ingredient) for three months. Although these medications are not yet approved for Long Covid, they are authorized for use in treating other health conditions. This study is adaptive, meaning it may adjust based on early results. In the second phase, the study could continue testing the most effective drug(s) against a placebo with new participants, explore combinations of drugs to see if they improve results, or discontinue the drugs if they prove ineffective or unsafe and test alternative treatments.

Conditions

  • Long COVID

Interventions

  • PirfenidoneDrug

    Initial dose titration: First week (days 1-7): 1 capsule (267 mg), 3 times daily (801 mg/day) Second week (days 8-14): 2 capsules (534 mg), 3 times daily (1602 mg/day) Maintenance dose: Third week and thereafter (days 15+): 3 capsules (801 mg), 3 times daily (2403 mg/day)

  • Placebo for pirfenidoneDrug

    First week (days 1-7): 1 capsule, 3 times daily Second week (days 8-14): 2 capsules, 3 times daily Third week and thereafter (days 15+): 3 capsules, 3 times daily

  • UpadacitinibDrug

    1 capsule (15 mg), once daily for 3 months

  • Placebo for upadacitinibDrug

    1 capsule, once daily for 3 months

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Symptom Burden Questionnaire (SBQ) SubscalesTime frame: The Phase 1 time frame is from enrollment on Day 1 through to the end of follow-up at Month 6, and the Phase 2 time frame will be determined based on the results of Phase 1.

Locations

10 sites in 7 countries. Site status is shown where the registry gives one.

  • Laura Rodriguez Research Institute

    San Diego, California · Recruiting

  • Ini-Fiocruz

    Rio de Janeiro, Rio de Janerio, Brazil · Recruiting

  • Institut de Recherches Cliniques de Montréal (IRCM)

    Montreal, Quebec, Canada · Recruiting

  • Centre de Recherche du CHUS (CRCHUS)

    Sherbrooke, Quebec, Canada · Recruiting

  • Università degli Studi di Modena e Reggio Emilia

    Modena, Italy · Not yet recruiting

  • INMI Lazzaro Spallanzani IRCCS

    Roma, Roma, Italy · Not yet recruiting

  • Sapienza Università di Roma

    Roma, Roma, Italy · Not yet recruiting

  • Family Centre for Research with Ubuntu (FAMCRU), Stellenbosch University

    Cape Town, Western Cape, South Africa · Not yet recruiting

  • Joint Clinical Research Centre (JCRC)

    Kampala, Kampala, Uganda · Not yet recruiting

  • University Teaching Hospital

    Lusaka, Lusaka Province, Zambia · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.